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Abstract
Background: The optical accessibility of the eye and technological advances in ophthalmic diagnostics have put
ophthalmology at the forefront of data-driven medicine. The focus of this study is rare eye disorders, a group of
conditions whose clinical heterogeneity and geographic dispersion make data-driven, evidence-based practice
particularly challenging. Inter-institutional collaboration and information sharing is crucial but the lack of
standardised terminology poses an important barrier. Ontologies are computational tools that include sets of
vocabulary terms arranged in hierarchical structures. They can be used to provide robust terminology standards and
to enhance data interoperability. Here, we discuss the development of the ophthalmology-related component of two
well-established biomedical ontologies, the Human Phenotype Ontology (HPO; includes signs, symptoms and
investigation findings) and the Orphanet Rare Disease Ontology (ORDO; includes rare disease nomenclature/nosology).
Methods: A variety of approaches were used including automated matching to existing resources and extensive
manual curation. To achieve the latter, a study group including clinicians, patient representatives and ontology
developers from 17 countries was formed. A broad range of terms was discussed and validated during a dedicated
workshop attended by 60 members of the group.
Results: A comprehensive, structured and well-defined set of terms has been agreed on including 1106 terms relating
to ocular phenotypes (HPO) and 1202 terms relating to rare eye disease nomenclature (ORDO). These terms and their
relevant annotations can be accessed in http://www.human-phenotype-ontology.org/ and http://www.orpha.net/;
comments, corrections, suggestions and requests for new terms can be made through these websites. This is an
ongoing, community-driven endeavour and both HPO and ORDO are regularly updated.
Conclusions: To our knowledge, this is the first effort of such scale to provide terminology standards for the rare eye
disease community. We hope that this work will not only improve coding and standardise information exchange in
clinical care and research, but also it will catalyse the transition to an evidence-based precision ophthalmology paradigm.
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Rare eye diseases (REDs) are a major cause of visual
impairment and blindness in children and young adults
[1, 2]. To date, according to Orphanet, over 1000 REDs
have been described; the majority of these conditions are
genetic and many of them have prominent extraocular
features [3]. Although each individual disorder is
rare (defined in the European Union as affecting less
than 1 in 2000 individuals [4]), collectively they are
common and their cumulative impact on affected
families and healthcare systems is substantial [5, 6].
The rarity of each RED, together with the significant
clinical and genetic heterogeneity that characterises this
group of conditions, can make precise diagnosis and
evidence-based management challenging. To improve
patient care and to obtain sufficient sample sizes for
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research, responsible sharing of knowledge and data
across centres and countries is required [7]. Adoption of
comprehensive phenotype and rare disease ontologies
enables this type of sharing by making data findable, ac-
cessible, interoperable, and re-usable (FAIR principles) [8].
Ontologies are computational tools assisting in the
description, organisation and analysis of data. An
ontology provides not only a standardised set of vo-
cabulary terms but also a classification of these entities
so that terms with related meanings are connected by
well-defined relationships. Central to each ontology
are terms, also known as classes, which are arranged
in a hierarchical and semantically informative struc-
ture from the general (high in the hierarchy) to the
specific (low in the hierarchy) [9–11] (Fig. 1; Add-
itional file 1: Figure S1).
This work focuses on developing the ophthalmology-
related component of two widely utilized biomedical
ontologies, the Human Phenotype Ontology (HPO) and
the Orphanet Rare Disease Ontology (ORDO) [3, 10, 12,
13]. Each term in HPO describes a distinct phenotypic
feature such as a symptom (e.g. photophobia) or a sign
(e.g. Haab’s striae), while each ORDO term corresponds
to a specific rare disorder (e.g. posterior polymorphous
corneal dystrophy).
To set a robust ontological foundation for ocular
phenotypes and REDs a multi-step approach was uti-
lized. The HPO project commenced in 2007 with the
initial aim of aiding rare disease phenotyping and
diagnostics [9]. Data from the Online Mendelian In-
heritance in Man (OMIM; https://omim.org/) database
were used for the construction of HPO and, over the
past decade, significant refinement and expansion oc-
curred through manual curation and careful mapping
to other resources including the Systematized Nomen-
clature of Medicine-Clinical Terms (SNOMED-CT;
https://www.snomed.org/snomed-ct) and the Inter-
national Statistical Classification of Diseases and
Related Health Problems (ICD; http://www.who.int/
classifications/icd/). The latest release of HPO (11/
2018) includes 1106 terms related to ocular pheno-
types. There are 842 textual and/or logical definitions
and 968 synonyms related to these terms; 1208 sub-
class relationships and 7702 annotations of ocular
phenotypes to 2770 rare disorders have been created.
A set of tools that can be used to explore HPO can
be found in https://hpo.jax.org/app/tools/hpo-browser
and https://hpo.jax.org/app/tools/workbench.
Orphanet is an international data resource that was
created in 1997 to address the scarcity and fragmen-
tation of information on rare diseases. This unique
database has grown substantially over the past 20
years by incorporating expert advice and through
extensive manual curation of medical literature.
Importantly, there is almost complete linkage of
Orphanet with SNOMED-CT and ICD, two resources
that are commonly used in electronic healthcare
records (EHRs) but are presently less rich in rare
disease related content. The Orphanet nomenclature
evolved into a formal ontology (ORDO) in 2014
and the latest version (11/2018) includes 1202
RED-related entries (including 146 groups, 834 disor-
ders and 222 subtypes) each having a unique, stable
ORPHA number. The Orphanet nomenclature can
be browsed in https://www.orpha.net and ORDO
is available at http://www.orphadata.org/cgi-bin/index.
php#ontologies.
Our efforts to enrich the ophthalmology-related
content of these two resources culminated in a 4-day
workshop in October 2017 (ERN-EYE Ontology meet-
ing, Mont Sainte-Odile, France). In this meeting, 60
members of the European Reference Network on rare
eye diseases (ERN-EYE) from 29 centres of 13 countries
[14] worked with international experts to enrich the
HPO and Orphanet classifications and to agree on a
broad range of terms. Briefly, the adopted approach
involved sharing existing HPO terms and Orphanet
classifications with all ERN-EYE members prior to the
workshop. Participants were distributed in six working
groups (retina, neuro-ophthalmology, paediatric oph-
thalmology, anterior segment, low vision, and genetic
diagnostics) who discussed issues and suggestions.
Patient representatives were also consulted and their
active participation at the workshop provided key in-
sights. Subsequent engagement of ERN-EYE members
has led to further refinement of the ontologies includ-
ing providing definitions and other relevant annota-
tions. Overall, 605 new HPO terms related to ocular
disease were added and over 400 terms were revised
(including adding definitions and/or synonyms, cor-
recting errors and removing/merging obsolete terms).
The Orphanet classification was fully restructured
with more than 67 groups created, 36 disorders intro-
duced, 90 entities removed/merged, and 131 modifications
made in the nomenclature. For further information on the
specific changes made as a result of the workshop please
see Additional file 1: Tables S1 and S2.
There are multiple advantages in using ontologies,
the most important one being enhanced data integra-
tion: by making data computationally accessible it is
possible to bridge the compatibility gap between differ-
ent healthcare systems, databases and languages. Also,
sophisticated cross-resource bioinformatics analyses
with data from other domains (e.g. genomic data) is
enabled. These features have made ORPHA numbers a
standard for rare disease coding in European health-
care systems and have led to the widespread adoption
of ontologies like HPO by global genomics initiatives
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(e.g. Matchmaker Exchange [15] and RD-Connect
[16]) and clinical genetic laboratories. Notably, both
ORDO and HPO are open-access, interoperable,
community-driven, available in multiple languages and
regularly updated (twice a year for ORDO, at least
quarterly for HPO). Requests for new terms or other
amendments can be made through the Orphanet and
HPO portals and we hope to engage all stakeholders
in this ongoing effort. The ERN-EYE remains com-
mitted to further improving these resources and
future plans include working on “layperson” terms for
ocular phenotypes (so that patients can also use
HPO) and on annotating each RED with HPO terms
(to enhance diagnostic accuracy) [17].
To our knowledge, this is the first effort of such
scale to provide terminology standards for the RED
community. The resources outlined in this article
have the potential to transform both routine care
(e.g. by integration in EHRs) and research (e.g.
recording clinical data in registries) for RED. We
believe that collaborative efforts like this not only
result in improved data classification and coding,
but also lead to growing acceptance of standard
nomenclatures among the RED community. Finally,
we hope that this work will catalyse responsible inter-in-
stitutional data sharing and facilitate the transition
to an evidence-based precision medicine paradigm
for RED [18].
Fig. 1 Example of hierarchical (tree) structure of data in the Human Phenotype Ontology (HPO). Ophthalmic findings in a child with PHACE
syndrome (posterior fossa anomalies, hemangioma, arterial lesions, cardiac abnormalities/coarctation of the aorta, eye anomalies) are shown.
Ontologies consist of several distinct elements including terms (nodes in the figure) and relationships (arrows in the figure). Each term can be
associated with annotated textual information known as metadata; these may include modifiers (blue squares), definitions and alternative/
secondary identifiers. Modifiers can be assigned to each term and may relate to severity (mild, moderate etc.), temporal pattern (acute, episodic,
etc.), age of onset (childhood onset, adult onset etc), progression (progressive, nonprogressive, etc.), laterality (right, bilateral etc) and spatial
pattern (central, generalized, etc.). The user can specify if a specific phenotype (HPO term) is present or absent in an individual. When a
phenotype/term is selected as present (e.g. terms corresponding to the five circles with thickened margins) then, by definition, all terms above
this term (coloured circles; colours only used to enhance visualisation) have to be present; this is because each term is connected with its parent
terms by an “is a” relationship. Therefore, the higher in the ontology a term is located, the more general it is and the lesser its information
content (defined as the negative logarithm of its probability) will be
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Additional file
Additional file 1. Example of hierarchical data structure in ORDO
(Figure S1), summary of the modifications made to HPO and ORDO as
part of this study (Table S1), and list of disease groups and specific
disorders introduced to ORDO as a result of the ERN-EYE Ontology meet-
ing (Mont Sainte-Odile, France, 10/2017) (Table S2). (PDF 428 kb)
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